CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics announced today that it has acquired two exclusive licenses from Harvard University to technologies for enhancing the activity of a key cellular protein clearance mechanism, the ubiquitin-proteasome pathway. The technologies, which include novel targets and small molecule compounds, contribute to the company’s innovative approaches to developing therapeutics for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, as well as orphan diseases, such as cystic fibrosis and lysosomal storage diseases. Financial terms were not disclosed.
